FGFR2 and cholangiocarcinoma: For instance, in patients diagnosed with FGFR2 fusion- or rearrangement-positive cholangiocarcinoma, significant improvements in patient outcomes were observed in treatment with futibatinib, a covalently binding inhibitor of FGFRs [54], and infigratinib, a selective, ATP-competitive inhibitor of FGFRs [55].